Detail akcie Castle Biosci Rg online

Business Summary: Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Castle Biosciences Inc revenues increased 5% to $257.2M. Net loss totaled $21.8M vs. income of $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Dermatological Cancer Company segment loss totaling $39M vs. income of $4.6M, United States segment loss totaling $39M vs. income of $4.6M.